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Abstract
Cytokines play a critical role in the normal development and function of the immune system.
On the other hand, many rheumatologic diseases are characterized by poorly controlled
responses to or dysregulated production of these mediators. Over the past decade
tremendous strides have been made in clarifying how cytokines transmit signals via pathways
using the Janus kinase (Jak) protein tyrosine kinases and the Signal transducer and activator
of transcription (Stat) proteins. More recently, research has focused on several distinct
proteins responsible for inhibiting these pathways. It is hoped that further elucidation of
cytokine signaling through these pathways will not only allow for a better comprehension of
the etiopathogenesis of rheumatologic illnesses, but may also direct future treatment options.
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gc = common g chain; CIS = cytokine inducible SH2 protein; IFN = interferon; IL = interleukin; Jak = Janus kinase; JH = Janus homology (domain);
MAPK = mitogen-activated protein kinase; PIAS = protein inhibitors of activated Stats; SCID = severe combined immunodeficiency; SH = src
homology (domain); SOCS = suppressor of cytokine signaling; STAM = signal transducing adaptor molecule; Stat = Signal transducers and acti-
vators of transcription; Th = T-helper (lymphocyte).
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Introduction
Since their discovery and cloning, it has become abun-
dantly clear that cytokines play critical roles in regulating
immune and inflammatory cells. For instance, the develop-
ment of lymphoid and myeloid cells is now known to be
controlled to a major degree by cytokines such as inter-
leukin (IL)-7, IL-3, granulocyte–monocyte colony-stimulat-
ing factor (GM-CSF), and granulocyte colony-stimulating
factor, among others. Similarly, numerous studies have
documented the role of IL-6 in promoting inflammatory
responses. Other cytokines can be classified as
immunoregulatory cytokines. For example, IL-2 controls
lymphoid homeostasis both positively and negatively; in
addition, the differentiation of CD4+ T-helper (Th) cells
into Th1 and Th2 subsets has been documented to be
controlled in large measure by cytokines. For instance,
IL-12 promotes the differentiation of naïve Th cells to
those that produce interferon (IFN)-g and lymphotoxin (Th1
cells), whereas IL-4 drives the differentiation of T cells to
those that secrete IL-4, IL-5, and IL-10 (Th2 cells).
Not only do these processes contribute to normal host
defence, but also to the pathogenesis of autoimmune
disease. Much research has focused on the roles that
cytokines play in diseases such as rheumatoid and psori-
atic arthritis, systemic lupus erythematosus, and even
such disparate illnesses as scleroderma and osteoarthritis.
It is clear that both the pathogenesis and clinical manifes-
tations of these debilitating diseases are at least in part
due to aberrant immune and inflammatory responses, both
of which are critically dependent on cytokines. In several
animal models of rheumatoid arthritis, most notably colla-http://arthritis-research.com/content/2/1/016
gen-induced arthritis in mice, disease susceptibility has
been shown to be highly dependent on immunoregulatory
cytokines. For instance, when susceptible mouse strains
are rendered genetically deficient in either IL-12 or the
IL-12 receptor, they develop a much milder manifestation
of arthritis when immunized with collagen compared to
normal animals. Even more strikingly, mice that are inca-
pable of producing IL-6 become totally resistant to
disease in response to collagen immunization.
Obviously, then, it is of great interest to understand the
molecular basis of cytokine action. Fortunately, the mecha-
nisms by which cytokines transmit signals from the cell
membrane to the nucleus have been studied extensively,
and knowledge of these pathways has increased tremen-
dously over the past several years. In particular, analysis of
mice and humans with cytokine receptor mutations or
mutations of signaling molecules has provided important
insights into the specific functions of these molecules; this
information is emphasized in the present review.
The present review focuses on signaling by receptors that
are members of two structurally related families, termed
type I and type II cytokine receptors. Type I cytokine
receptors include those for cytokines such as erythropoi-
etin, prolactin, growth hormone, thrombopoietin, granulo-
cyte colony-stimulating factor, and GM-CSF. In addition,
many, but not all of the receptors for different interleukins
are part of this family: IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9,
IL-11, IL-12, IL-13, and IL-15. The type II cytokine recep-
tors include those for the IFNs (IFN-a, IFN-b, and IFN-g)
and IL-10. Of note, the receptors for IL-1, IL-18, IL-8,
transforming growth factor-b, and tumor necrosis factor
are not part of this family; despite their importance to
immune-mediated disease, the signaling pathways used
by these cytokines are not discussed here.
Type I and II cytokine receptors lack intrinsic kinase activity
and instead rely on Janus kinase (Jak) proteins to initiate
signaling. Cytokine binding to these receptors can activate
a variety of pathways within cells including mitogen-acti-
vated protein kinases (MAPKs) and phosphoinositide 3¢
kinase. However, the discovery of a new family of tyrosine
phosphorylated transcription factors, the Signal transducer
and activator of transcription (Stat) family, provided great
insight into the action of cytokines. Recently, research has
focused on molecules that attenuate cytokine signaling. Of
considerable interest is the suppressor of cytokine signal-
ing (SOCS) family of molecules [1–12].
Jaks
In contrast to other tyrosine kinase families, the Jak family
is rather small. There are only four known mammalian Jaks
– Jak1, Jak2, Jak3, and Tyk2 – which were identified in the
early 1990s by techniques that capitalized on homology of
their kinase domains to other tyrosine kinases [13–16].
Since the discovery of these family members, no new
mammalian members have been identified, suggesting
that they may comprise the entire family. Teleost and avian
Jaks have been identified, as has a single Drosophila Jak;
thus, these critical signaling molecules are highly con-
served throughout evolution [17–19]. Shortly after their
discovery, their functional importance in IFN and cytokine
signaling was established [1,20]. It was first shown that
Jaks are essential for IFN signaling using a panel of cell
lines that were resistant to IFNs [21–23], and subse-
quently, type I cytokines were also found to activate Jaks;
in fact, all type I and II cytokines activate Jaks in some
combination [6,24–28]. It was also shown that Jaks physi-
cally associate with cytokine receptors. For the IFN-a
receptor, the presence of Tyk2 is required for appropriate
receptor expression on the cell surface; this does not
appear to be the case for other cytokines, however.
Jak function
Jak3
Jak3, in marked contrast to the relatively ubiquitous
expression of Jak1, Jak2, and Tyk2, has a much more reg-
ulated and specific tissue expression. It is constitutively
expressed at high levels in natural killer cells and thymo-
cytes, and is inducible in T cells, B cells, and myeloid cells
[16,29–32]. Jak3 is activated by a limited number of
cytokines, only those receptors that use the common g
chain (gc) (IL-2, IL-4, IL-7, IL-9, and IL-15) [26,27,33–35]
(Table 1). This is explained by the fact that Jak3 specifi-
cally associates with gc, and IL-2 and IL-4 signaling is
markedly compromised in cells lacking Jak3 [36,37].
The pivotal function of Jak3 was established when a form
of human severe combined immunodeficiency (SCID) was
found to result from Jak3 mutations [38,39]. As was pre-
dicted on the basis of the association of Jak3 with gc, the
phenotype of these patients was quite similar to that seen
in patients with X-linked SCID, which results from a muta-
tion in the gc [40]. These patients lack T cells and natural
killer cells and have dysfunctional B cells. Jak3 knockout
mice were subsequently generated that also have defects
in the same cell lineages (T, B, and natural killer cells)
[41–44].
Because Jak3 is activated by all of the gc cytokines, the
question arises as to how the deficient signaling by these
various cytokines relates to Jak3 and gc deficiency. The
phenotype of Jak3 SCID and X-linked SCID is most similar
to IL-7 and IL-7 receptor gene-targeted mice [45–47]. The
lack of IL-7 signaling can clearly result in SCID in mice,
and recently it was documented that a subset of patients
with autosomal recessive SCID have IL-7 receptor muta-
tions [48]. One notable feature is that these patients do
have natural killer cells, indicating that IL-7 signaling is not
essential for natural killer cell development. In this regard it
is important to note that IL-15 receptor a chain knockoutArthritis Research    Vol 2 No 1 Ortmann et al
mice lack natural killer cells [49]. Thus, the SCID pheno-
type associated with Jak3/gc deficiency largely results
from defective IL-7 and IL-15 signaling. It should be noted,
however, that the phenotypes of Jak3 and gc deficient
mice and humans differ somewhat. Whereas human SCID
patients have dysfunctional B cells and few, if any, T cells,
deficient mice lack B cells and have reduced T cell
numbers. The explanation for this difference is unclear at
present. It should be noted that the T cell defect in human
Jak3 SCID is not absolute; some patients do develop
some T cells [50].
Somewhat surprisingly, IL-2, IL-2 receptor a chain, and
IL-2 receptor b chain knockout mice exhibit lymphoprolifer-
ative and autoimmune disease [51–54], an abnormality
that has been attributed to defective apoptosis of acti-
vated T cells. T cells from humans with Jak3 SCID and
Jak3/gc
–/– mice are abnormal in that they express activa-
tion markers [41,55]; impaired negative thymic selection
has been postulated as one mechanism, but an alternative
explanation is that absence of IL-2 signaling results in
impaired apoptosis.
Although we and others previously showed that myeloid
cells express Jak3 upon stimulation with a variety of
cytokines and proinflammatory stimuli, no abnormal func-
tion has been reported in this cell lineage due to the lack
of Jak3 expression [56]; the function of Jak3 in this
lineage, therefore, remains unclear.
Importantly, after treatment with bone marrow transplanta-
tion, no significant defects have been reported outside the
immune system in Jak3 and gc deficient humans. This
argues that the functions of Jak3 and gc are truly limited to
the immune system, which is consistent with the relative
tissue specificity of this molecule. The specificity of the
defects suggests that Jak3 or the Jak3–gc interaction may
represent a useful target for the development of novel
immunosuppressants [33,38,39].
Jak1, Jak2, and TyK 2
As stated previously, Jak1 and Jak2 have a wide tissue
expression and are activated by a variety of cytokines
(Table 1). Specifically, IFN-a/b signaling requires Jak1 and
Tyk2; the a subunit of the IFN-a/b receptor associates
with Tyk2, and the b subunit with Jak 1 [57–59]. In con-
trast, IFN-g requires Jak1 and Jak2 [1,21–23,60]. In this
circumstance, the IFN-g receptor  a subunit associates
solely with Jak1 and the b subunit only with Jak2 [5]. Jak1
is also activated by gc cytokines and associates with the
ligand-specific receptor subunit. Hormones such as
growth hormone and erythropoietin predominantly associ-
ate with and activate Jak2 [24,25], but Jak2 also associ-
ates with the common b chain, a shared subunit for IL-3,
IL-5, and GM-CSF [61]. IL-6 and related cytokines can
activate Jak1, Jak2, or Tyk2; gp130, the shared subunit of
this family of receptors, can bind each of these Jaks [62].
Finally, the IL-12 receptor b1 chain associates with Tyk2
and the b2 chain associates with Jak2 [63].
As might be expected on the basis of the cytokines that
activate them, mice that lack either Jak1 or Jak2 have more
diverse abnormalities. Like Jak3 knockout mice, Jak1–/–
mice have SCID. In contrast to Jak3 knockouts, though,
Jak1 deficient mice die perinatally as a result of an incom-
pletely defined neurologic defect [64]. In addition, they fail
to manifest biologic responses to all receptors that utilize
this kinase, including all type II cytokine receptors,
cytokine receptors that utilize the gc subunit for signaling,
and the family of cytokine receptors that depend on the
gp130 subunit for signaling.
Jak2 deficiency is embryonically lethal, because these
mice fail to develop erythroid cells [65,66]. Interestingly,
this phenotype is more severe than that seen in erythropoi-
etin receptor deficient mice, perhaps due to the necessity
of signaling through other Jak2-requiring receptors such
as IL-3 for efficient erythropoiesis. Enhanced signaling
through Jak2 has also been implicated in the pathogene-
sis of leukemia. Chromosomal translocations in several
patients with leukemia were characterized and shown to
fuse the 3¢ portion of Jak2 to the 5¢ region of TEL, a gene
encoding a member of the ETS transcription factor family.
The TEL-Jak2 fusion protein includes the catalytic domain
of Jak2 and the TEL-specific oligomerization domain. TEL-
induced oligomerization of TEL-Jak2 resulted in the consti-
tutive activation of its tyrosine kinase activity and conferred
cytokine-independent proliferation to the interleukin-3-
dependent Ba/F3 hematopoietic cell line [67,68]. These
findings underscore the importance of Jak2 mediated sig-
naling in driving proliferation and differentiation in both
myeloid and lymphoid cells.
Tyk2 knockout mice have not been reported as of yet, and
no known human disorders have been linked to a defect in
this Jak, so the cytokines for which Tyk2 signaling is
uniquely responsible have not been ascertained. Based on
the findings with deficient cell lines, the expectation is that
IFN a/b actions will be impaired in such mice.
Jaks and noncytokine receptors
Since the discovery of the Jaks, occupancy of a vast array
of receptors other than type I and II receptors have been
shown to induce Jak phosphorylation and/or activation. To
date, however, it has not been proved that Jaks are essen-
tial, nonredundant components of the signaling pathways
of noncytokine receptors. For instance, although CD40
was found to associate with Jak3, no defect in CD40 sig-
naling was apparent in Jak3 deficient cells [69,70]. At
present, the only receptors documented to be absolutely
dependent on Jaks for signaling are type I and II cytokine
receptors. Whether this small family of tyrosine kinases isTable 1
Association of Janus kinases (Jaks), Signal transducers and activators of transcription (Stats), and suppressors of cytokine signaling (SOCSs) with cytokine receptors and
phenotype of knockout mice.
Jak/Stat/SOCS Cytokines Deficient mice
Jak1 g gc cytokines, gp130 cytokines, IL-10, IFN-a a, IFN-b b, IFN-g g, IL-13 Neurologic defect (?), mice die perinatally
Jak2 Erythropoietin, b bc cytokines, gp130 cytokines, IL-13, IL-12, GH, prolactin, Embryonically lethal, failed to develop red blood cells
thrombopoietin, IFN-g g
Jak3 IL-2, IL-7, IL-15, gc cytokines SCID
Tyk2 gp130 cytokines, IL-13, IL-12, IFN-a, IFN-b, IL-10 Not yet reported
Stat1 IFN-a a, IFN-b b, IFN-g g, IL-2, IL-6, IL-10 Susceptibility to viral and some bacterial infections
Defective signaling in response to IFNs
Impaired tumor rejection
Stat2 IFN-a, IFN-b Defective signaling in response to IFNs*
Stat3 LIF, IL-10, IL-6, other gp130 cytokines, gc cytokines, GH Embryonically lethal
Targeted disruption in macrophages and neutrophils showed defective
IL-6 and IL-10 signaling
Chronic enterocolitis
Conditional knockouts showed suppressed epithelial apoptosis and 
delayed mammary gland involution
Stat4 IL-12 Defective Th1 development
Stat5a Prolactin, other gc cytokines, other bc cytokines, GH, thrombopoietin Defective lobuloalveolar development in breast
Stat5b GH, other gc cytokines, bc cytokines, prolactin, thrombopoietin Required for sexual dimorphism
Stat5a/b GH, IL-2, erythropoietin Infertile, smaller body size
Impaired cell-cycle progression of peripheral T cells
Fetal anemia (?)
Stat6 IL-4, IL-13 Defective Th2 development
Stat4/6 No Th2 cells in vitro
SOCS-1 IFN-g g, IL-6, GH, thrombopoietin, OSM, LIF Perinatal lethality, hyper-responsiveness to IFN-g
SOCS-3 Erythropoietin, GH, IL-2, leptin, CNTF, IL-11, IL-10 Embryonic lethality, ? due to erythrocytosis
g Chain (gc) cytokines: interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15. gp130 cytokines: IL-6, IL-11, oncostatin M (OSM), ciliary neurotropic factor (CNTF), leukemia inhibitory factor (LIF), CT-1, IL-12,
Leptin. b chain (bc) cytokines: IL-3, IL-5, granulocyte–macrophage colony-stimulating factor (GM-CSF). Bold letters indicate cytokines that have been shown to be essential in knockouts.
*Schindler C, personal communication. SCID, severe combined immunodeficiency; FGF, fibroblast gowth factor; GH, growth factor; IFN, interferon.
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6dedicated to signaling by this class of receptors or
whether wider functions exist remains to be determined;
this is one of the most interesting remaining questions that
pertain to the biology of the Jaks.
Jak structure
The three-dimensional structure of the Jaks is presently
unknown. This is no doubt partly because they are rela-
tively large kinases of more than 1100 amino acids with
apparent molecular weights of 120–130 kDa. Their mes-
senger RNA transcripts range from 4.4 to 5.4 kilobases in
length. Multiple spliced forms of Jak3 have been identified,
including a variant that lacks a segment of the catalytic
domain [29,71,72]. It is intriguing to speculate that a natu-
rally occurring dominant negative form of Jak3 may have
regulatory function, but this has yet to be proved.
Jaks have seven regions of homology termed Janus homol-
ogy (JH) domains 1–7 (Fig. 1), and the carboxy-terminal
tyrosine kinase, or JH1 domain, shares the features of
other tyrosine kinase domains. For example, phosphoryla-
tion of tyrosine residues in the activation loop of kinases
such as the insulin receptor play an important role in regu-
lating phosphotransferase activity [73]. A number of
autophosphorylated sites are being identified in Jaks, two
of which reside within the putative activation loop.
Depending upon the specfic Jak, however, mutations at
these sites appear to have slightly different functional con-
sequences. That is, mutation of tyrosine 1007 abrogated
any signaling capacity of Jak2, whereas mutations in both
the corresponding tyrosine residues and the adenosine
triphosphate binding site were required to abolish activity
of Tyk2 completely [74,75]. In contrast, mutations of Y981
in Jak3 actually increased activity [76]. Thus, there may be
subtle differences in the regulation of catalytic activity of
each Jak. The molecule src homology (SH)2Bb, an SH-2
domain containing protein, associates with Jak2 and
increases its catalytic activity in response to growth
hormone, but the mechanism of this regulation has not
been determined [77,78].
The hallmark of the Jak family of protein tyrosine kinases is
the existence of tandem kinase and pseudokinase
domains; it is this feature that gives the Jaks their name,
and among mammalian tyrosine kinases only the Jaks have
this domain. Like the Roman god of gates and doorways,
the Jaks are ‘two-faced’. The pseudokinase domain is also
termed the JH2 domain. Although it has overall similarity to
kinase domains, the JH2 domain lacks critical residues
that are required for phosphotransferase activity; rather,
the function of this domain appears to be to regulate cat-
alytic activity. Mutations or deletions of this region have
complicated effects that either inhibit or enhance catalytic
function, depending upon the exact mutation generated
[79,80] (Chen M, et al, unpublished data). Importantly,
Jak3 SCID patients have been identified with mutations in
this region, underscoring its critical function [50]. Another
function suggested for the JH2 domain is as a docking
site for Stats [81].
Although it has not been well characterized for all of the
Jaks, the amino-terminus appears to confer binding to the
appropriate cytokine receptor [79,82–84]. For Jak3, at
least, the amino-terminal JH6 and JH7 domains are suffi-
cient to confer binding specificity to gc [85,86]. For other
Jaks, the amino-terminus is clearly involved in receptor inter-
actions, but may extend beyond the JH6 and JH7 domains
[87,88]. The region of the cytokine receptor to which Jaks
bind has been much better characterized and is found in the
membrane proximal region (reviewed in Ihle, 1995 [28]).
Signal transducing adaptor molecule (STAM), a 70-kDa
adaptor molecule that is phosphorylated in response to IL-2,
IL-4, GM-CSF, epidermal growth factor and platelet-derived
growth factor, binds to both Jak3 and Jak2, and couples
cytokine stimulation to DNA synthesis [89]. STAM is a mol-
ecule that associates with Jaks and may enhance the forma-
Arthritis Research    Vol 2 No 1 Ortmann et al
Figure 1
Structure of Janus kinases (Jaks), signal transducers and activators of
transcription (Stats), and suppressors of cytokine signaling (SOCS).
Regions of homology shared by Jaks have been termed Jak homology
(JH) domains. JH1 is a kinase domain and JH2 is a pseudo-kinase
domain. The amino-terminus of the Jaks appears to be important for
association with cytokine receptors subunits. Stats have a conserved
tyrosine residue, phosphorylation of which allows Stat dimerization; a
src homology (SH2) domain that mediates the dimerization; and an
amino-terminal region that is known to play a role in the dimerization of
Stats dimer. The amino-terminal, carboxy-terminal and coiled-coil
regions of Stats can interact with other transcription factors. SOCS
proteins share a similar strucuture with a central SH2 domain, a region
at the amino-terminus that is variable in both length and in amino acid
sequence, and a region of homology at the carboxy-terminus termed
the ‘SOCS box’.
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Amino Acidtion of Jak–receptor complexes (authors’ unpublished
observations). Two STAM-associated molecules, Hrs and
AMSH, have been hypothesized to act downstream of Jaks
in cytokine signaling pathways [90,91].
Many tyrosine kinases have intrinsic SH2 and SH3
domains that mediate protein–protein interactions.
Although the JH4 domain has overall homology to SH2
domains, mutation of the critical Arg residue, which would
be expected to bind phosphotyrosine, had no effect on
signaling. Thus, the function of this segment remains
unclear at present [15,84].
Binding of cytokines to type I and II receptors has been
suggested to initiate signaling by effecting homodimer-
ization or heterodimerization of the receptor subunits,
which in turn leads to the apposition of Jaks. This may
allow transphosphorylation of the Jaks at sites within
their activation loops, thus enhancing catalytic activity. A
more recently proposed mechanism [92,93] is that
ligand-induced allosteric alteration of the receptor itself
leads to Jak activation. For receptors that heterodimerize
(most of the IL and IFN receptors), heterodimerization of
different Jaks also occurs, and the Jaks are interdepen-
dent for activation. For instance, in cells that lack Jak1,
no phosphorylation of Tyk2 or Jak2 was observed upon
stimulation with IFN [60], and conversely no phosphory-
lation of Jak1 was seen in cells lacking Jak2 or Tyk2. In
Jak3 deficient cells, no phosphorylation of Jak1 occurs in
response to IL-2 [36].
Regardless of the precise mechanism, after activation the
Jaks phosphorylate receptor subunits on tyrosine
residues, enabling the recruitment of proteins with SH2 or
phosphotyrosine binding domains. These proteins are
then phosphorylated by Jaks. A number of signaling path-
ways, such as the Ras–Raf–MAPK pathway and the phos-
phoinositide 3¢ kinase pathways are activated in response
to cytokines; the significance of these pathways in
immune function has been extensively reviewed elsewhere
and is not discussed here [94–99]. However, the function
of another class of SH2-containing molecules, the Stats,
is discussed in detail.
Stats
By purifying factors bound to promoters of IFN-inducible
genes, Darnell and coworkers [100] cloned the first
members of the Stat family. The IFN-a induced complex
comprised a 91-kDa polypeptide, which later became
known as Stat1; a 113-kDa protein (Stat2); and p48, a
member of the IFN regulatory factor family. An IFN-g
induced complex, g activated factor, turned out to be com-
posed of Stat1 only [101].
Following the discovery of Stat1 and Stat2, the cloning of
the remaining family members, Stat3, Stat4, Stat5a,
Stat5b, and Stat6, quickly ensued [9,102–110]. Most
Stats are approximately 750 amino acids long, but Stat2
and Stat 6 are larger (850 amino acids). These transcrip-
tion factors were immediately recognized as a novel family,
in that they had SH2 domains and were themselves tyro-
sine phosphorylated. Thus, a new signaling paradigm
emerged (Fig. 2). Stats are latent cytosolic transcription
factors that are recruited to phosphorylated cytokine
receptors via their SH2 domains [111–114]. The Stats
are then phosphorylated themselves by Jaks, they het-
erodimerize or homodimerize via reciprocal SH2–phos-
photyrosine interactions, and translocate to the nucleus to
regulate gene transcription.
Stat structure
In contrast to the Jaks, the structure of the Stat molecules
has been reasonably well characterized [115–117] (Figs 1
and 3). Overall, the structure of the Stats is similar to that of
other transcription factors such as nuclear factor-kB and
p53. The dimeric molecule forms a C-clamp structure
around the DNA, but, unlike nuclear factor-kB and p53,
there are fewer direct contact sites with the DNA backbone.
Rather, the nutcracker-like structure of the Stats is largely
dependent upon SH2–phosphotyrosine interactions. Stats
have a conserved amino-terminal protein–protein interaction
domain, followed by a segment (the coiled-coil domain) with
multiple protruding a-helices. This is followed by the actual
DNA binding domain, a linker domain, the SH2 domain, a
conserved site of tyrosine phosphorylation, and a variable
carboxy-termini transcriptional activation domain.
Amino-terminal dimer–dimer interaction domain
With the exception of Stat6, Stats bind somewhat indis-
criminately to the same consensus sequences; it is
notable that clustered imperfect Stat binding sites are
found in a number of relevant cytokine inducible promot-
ers. Even though Stats bind poorly to these sites, cooper-
ative dimer–dimer interactions can occur [118]. This is
mediated by the conserved amino-termini of Stats, which
consists of eight helices that form hook-like structures,
facilitating these interactions. Perhaps unimportant for
Stat binding to a single consensus binding site [119],
these domains appear critical for binding to imperfect
sites [120]. Combinatorial binding might be one mecha-
nism of achieving more specificity in signaling.
Coiled-coil domain and association with other transcription
factors
Consisting of four a-helices, the coiled-coil domain from
amino acids 136–317 provides a structure suitable for
many protein–protein interactions. The coactivator proteins
p48 and p300/CBP have been shown to interact with
Stats through this region [121–125], as well as another
protein, Nmi [126]. Other transcription factors have been
shown to associate with Stats such as the glucocorticoid
receptor (with Stat5a and Stat5b), Sp-1, c-Jun, and
http://arthritis-research.com/content/2/1/016nuclear factor-kB, but the exact domain interactions have
yet to be mapped [127–132].
DNA binding domain
The DNA binding region of Stats resides within the central
171 amino acids, but relatively few direct contacts exist.
Rather, the clamp-like structure is imparted by phospho-
tyrosine–SH2 interactions [115,116]. Stats bind two
types of DNA motif: IFN-stimulated response elements
(consensus: AGTTTNCNTTTCC) and g-activated sequence
elements (consensus: TTCNNNGAA). Stat1, Stat2, and
p48 bind to IFN-stimulated response elements, whereas
Stat1, Stat3, Stat4, Stat5a, and Stat5b bind to g-activated
sequence element sites. Stat6 binds a similar but distinct
site: TTCNNNNGAA.
The src homology 2 domain and tyrosine phosphorylation site
The SH2 domain (amino acids 600–700) serves two critical
functions: to allow Stats to bind phosphorylated receptor
subunits and be phosphorylated themselves by Jaks on a
conserved tyrosine residue; and to enable Stat dimerization
and DNA binding. The crystal structure of a Stat–DNA
complex underscores the importance of the SH2 domain, as
the SH2–phosphotyrosine interaction forms the hinge of the
clamp that is largely responsible for DNA binding (Fig. 3).
Transcriptional activation domain
Stat1, Stat2, and Stat5 have been documented to have
carboxy-terminal transcriptional activation domains
[119,133–137]. In addition to tyrosine phosphorylation, it
has been shown that Stat1, Stat3, Stat4, and Stat5 are
also phosphorylated on serine residues in response to
cytokine stimulation [133,138,139]. For these proteins, a
conserved site of serine phosphorylation, residing in a con-
sensus sequence for MAPK-mediated phosphorylation has
been mapped within the carboxy-terminal transcriptional
activation domain [135,140] (Visconti et al, unpublished
data). However, the functional significance of Stat serine
phosphorylation and the identity of the kinase(s) responsi-
ble for this event remain deeply controversial. Recently, a
large number of reports have been published that link
STAT serine phosphorylation to the activation of various
MAPKs. Notably though, they provide significantly diver-
gent results, perhaps due to the differences in the Stat pro-
teins investigated and in the systems utilized [141–146].
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Figure 2
Model for cytokine signal transduction. Cytokines associate with
cytokine receptor subunits and activate janus kinases (Jaks). The Jaks
in turn phosphorylate tyrosine-based docking sites on the receptor.
signal transducers and activators of transcription (Stats) then bind via
their src homology (SH)2 domains. The STATs are then
phosphorylated by the JAKs, form homo-hetero-dimers and then
translocate into the nucleus, where they bind target sequences like g-
activated sequence (GAS) motif. Transcriptional activation of genes
typically requires the coordinated function of multiple accessory
transcription factors. Additionally, serine phosphorylation of some Stats
may be important for maximal transcription of target genes.
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Figure 3
Signal transducer and activator of transcription (Stat) binding to DNA.
In this two-dimensional model, the heterodimerized or homodimerized
Stat molecule binds to the appropriate DNA sequence via a ‘C clamp’
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binding domain, other regions of the Stat molecule may also be
important in DNA interactions. Tetramerization of the Stats may allow
for an even greater degree of stability in DNA binding to adjacent
imperfect Stat binding sites; this is mediated by the Stat amino-
terminus (not shown). Also not shown in this illustration is the Stat
transcriptional activation domain.
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PThus, it has been reported that p38, which is activated in
response to IFNs, is indispensable for Stat1 serine 727
phosphorylation and transcriptional activity [145]. Accord-
ingly, we have found that IL-12-induced Stat4 serine 721
phosphorylation and transcriptional activity requires p38
activity (Visconti et al, unpublished data). Other findings
indicate that JNKs, but not p38, mediate Stat3 serine 727
phosphorylation in response to various stress treatments
and that this event results in the inhibition of Stat3 activity
[146]. In contrast, it has been shown that both JNKs and
p38 are required for STAT3 transcriptional activity induced
by the Src oncoprotein [143]. Other MAPKs, including
extracellular signal related kinase family members, can also
phosphorylate serine residues in Stat proteins and activate
them [147,148]. Others have found, however, that signal-
ing through the extracellular signal related kinase pathway
can also downregulate Stat activity [149]. The most plausi-
ble hypothesis at the moment is that the effect of serine
phosphorylation of Stat proteins depends on the cell type
and on the class of serine kinases activated in response to
different extracellular stimuli.
Nuclear translocation
Stats lack a classic nuclear localization signal, and in
general dimerization of the Stats is believed to be essential
for nuclear localization. This appears not to be sufficient,
however, and sequences in the amino-terminus contribute
to nuclear translocation (and perhaps deactivation, as well)
[150]. For Stat1 at least, nuclear import has been shown to
be dependent upon the activity of the small guanosine
triphosphatase Ran and may involve the importin receptor
[151–154]. One group has hypothesized that Stats may
translocate to the nucleus via the nuclear localization signal
of the ligands or receptors themselves, but the importance
of this possibility remains to be established [155,156].
Finally, regulation of nuclear export of the Stats may also be
an important means of nuclear localization. In any case, it is
very clear that much needs to be learned about the regula-
tion of Stat intracellular trafficking.
Stat function
Stat1
Stat1 has been shown to be activated by the IFNs,
cytokines such as IL-2, IL-6, and IL-10, and noncytokine
signals such as epidermal growth factor (Table 1). Not
surprisingly, Stat1 knockout mice were found to be highly
susceptible to viral and some bacterial infections, reminis-
cent of defects observed in IFN-a receptor and IFN-g
receptor knockout mice and IFN-g receptor deficient
humans [157–160]. Interestingly, defects in signaling by
cytokines other than IFNs have not been reported, but it
does seem to be important for the fibroblast growth
factor-mediated growth inhibition of chondrocytes [161].
A role for IFN-g signaling through Stat1 for tumor surveil-
lance has recently been underscored. Mice deficient in
Stat1 or the IFN-g receptor were much more susceptible
to tumor development when challenged with a chemical
carcinogen, and when bred with mice deficient in the
tumor suppressor p53 gene, these mice developed a
broader spectrum of tumors compared with mice lacking
p53 alone [162]. A recent study [163] has shown that
Stat1 deficient mice are unable to clear immunogenic
tumors that their wild-type littermates easily controlled,
and that they are unable to reject poorly immunogenic
tumors when immunized with an IL-12 based vaccine.
Severe defects in lytic activity in both T and natural killer
cells were also noted.
Stat1 has additional functions in regulating apoptosis.
That is, tumor necrosis factor-a dependent apoptosis is
impaired in Stat1 deficient mice because of reduced
expression of the caspases Ice, CPP32, and Ich-1 [164].
Unlike its role in mediating cytokine dependent gene
expression, however, Stat1 dimerization does not appear
to be necessary for the regulation of these genes,
because an SH2 mutant Stat1 supports expression. The
mechanism by which this occurs is obscure, particularly in
view of the structural information present. The importance
of Stat1 in apoptosis mediated by type I cytokines was
further underscored when it was found that Stat1–/– mice
were resistant to virus-induced apoptosis [165].
Stat2
Like Stat1, Stat2 is also activated by interferons; indeed,
only IFN-a/b has been reported to activate Stat2
(Table 1). Unlike other Stats, it requires Stat1 and p48 for
interaction with DNA [166]. As of yet, Stat2 knockout
mice have not been reported, but evidently they are
severely deficient in IFN-a/b signaling, as might be
expected (Schindler C, personal communication).
Stat3
Stat3 was first identified as a factor activated by cytokines
signaling through gp130 (IL-6, leukemia inhibitory factor,
and ciliary neurotropic factor). Stat3 deficiency is embry-
onically lethal, perhaps due to the absence of leukocyte
inhibiting factor function, as well as its role in maintaining
stem cell pluripotency [167,168]. In contrast, gene target-
ing of Stat3 only in myeloid cells produced an exagger-
ated inflammatory response, resulting in premature death
largely due to impaired IL-10 function [169]. These
animals became highly susceptible to endotoxic shock
with increased production of inflammatory cytokines such
as tumor necrosis factor-a, IL-1, IFN-g, and IL-6. The sup-
pressive effects of IL-10 on the production of inflammatory
cytokines by macrophages and neutrophils was com-
pletely abolished, and these mice developed chronic ente-
rocolitis with age. Additionally, these mice manifested an
exaggerated Th1 response, which may also help to explain
the inflammatory bowel disease seen. These results might
suggest a role for abnormal Stat3 signaling in other
http://arthritis-research.com/content/2/1/016autoimmune processes, but no studies have been pub-
lished to date. Although it is clear that Stat3 is essential
for appropriate IL-10 signaling, its function for other
cytokines remains unclear because of the embryonic
lethality seen in Stat3 knockout embryos.
Stat4
Stat4 is activated by a limited number of cytokines; IL-12
is the predominant cytokine that activates Stat4 in mice,
whereas in humans both IFN-a/b and IL-12 activate it.
More recently it has been shown that IL-2 is capable of
activating Stat4 in natural killer cells [170]. Of note,
though, Stat4 deficient mice only demonstrate defects of
impaired IL-12 responses (ie defective Th1 development
and impaired cell-mediated immune responses), a pheno-
type similar to that seen in IL-12 and IL-12 receptor knock-
out mice and IL-12 receptor deficient humans [171–174].
Although predominantly expressed in lymphoid cells, Stat4
has recently been found to be inducibly expressed in acti-
vated macrophages, most notably those found in synovium
from rheumatoid arthritis patients (Frucht et al, submitted).
The target genes of Stat4 in macrophages are currently
unknown, but it is interesting to speculate that
macrophages may provide some functions of cellular
immunity previously assigned only to lymphoid cells.
Stat5
Encoded by two genes, Stat5a and Stat5b share 93%
identity at the protein level [109,175], and are both acti-
vated by a plethora of cytokines, including prolactin,
growth hormone, erythropoietin, thrombopoeitin, and IL-2.
The development of knockout mice, however, underscores
the very different biologic functions they each serve;
Stat5a knockout mice have impaired mammary gland
development [176], whereas Stat5b deficient mice are
defective in both sexually dimorphic growth as well as in
growth hormone dependent regulation of liver gene
expression [177].
To assess potential redundancy in function, Stat5a/Stat5b
double knockouts were created [178]; one-third of these
mice died within 48 h of birth, with the surviving mice
developing a smaller than normal body size, which was
apparently due to aberrant growth hormone signaling.
Despite the fact that lymphoid development is normal, T
cells are hyporesponsive to IL-2, and these animals
develop lymphoproliferative disease, similar to that in IL-2,
IL-2 receptor a chain and IL-2 receptor b chain deficient
mice [179]. These results underscore an essential role for
Stat5 for IL-2 signaling; whether Stat5a or Stat5b individu-
ally are critical is somewhat controversial at present,
because several studies have clearly shown that IL-2
responsiveness is impaired in either Stat5a or Stat5b defi-
cient mice [180,181]. Clinically, adult females are infertile,
but unlike Jak2 knockout mice, which have no blood, these
animals are only moderately anemic; the severity of
anemia, however, is also a point of contention [182] (Ihle
J, personal communication).
Of additional interest is the current controversy regarding
the role of Stat5 in T-cell receptor-mediated signaling. Ini-
tially found not to be involved with T-cell receptor signaling
[183], a more recent study has shown that Stat5 phos-
phorylation induced by T-cell receptor crosslinking is abol-
ished in lck deficient mice [184]. Other studies [185] have
suggested a role for Stat3 but not Stat5 in T-cell receptor-
mediated signaling; the different results may reflect the dif-
ferent model systems used. Nonetheless, the potential
significance of antigen-mediated signaling through the
Stats remains intriguing.
Stat6
Stat6 was originally identified as an IL-4 inducible tran-
scription factor [106]. It was therefore not surprising to
find that Stat6 deficient mice failed to develop Th2 immu-
nity in response to IL-4 or IL-13, were unable to upregu-
late cell surface expression of major histocompatibility
complex class II, CD23, or IL-4 receptor a chain in
response to IL-4, and failed to produce immunoglobulin E
in response to cross-linking of surface immunoglobulin D
[186–189]. Accordingly, lack of Stat6 dramatically attenu-
ates allergic and asthmatic diseases in several animal
models [190–193]. Stat6 deficient animals are also
unable to clear parasites [194]. Remarkably, a recent
study of Stat6 knockout mice in a murine acquired
immune deficiency syndrome model revealed normal
serum immunoglobulin E levels and lymphoproliferation,
indicating that B cells from mice with murine acquired
immune deficiency syndrome activate unique IL-4-inde-
pendent and STAT6-independent signaling pathways for
B-cell activation and differentiation [195].
The generation of Stat4/Stat6 double knockout mice has
provided an interesting model system for the study of
Th1/Th2 differentiation, a complex and exciting topic in
immunology today. Interestingly, these mice develop Th1
responses, suggesting that Stat4 may be dispensable for
Th1 differentiation in the absence of Th2 responses [196].
Activation of signal transducers and activators of transcription
by noncytokine receptors
As with the Jaks, ligation of many receptors has been
reported to activate various Stats. As discussed above, T-
cell receptor crosslinking, for instance, has been reported
to activate Stats, but this remains controversial [179,184,
197]. Less controversial are the findings that epidermal
growth factor, angiotensin II, and other ligands activate
Stats [198–203]. Through the use of knockout mice or
deficient cells, however, the essential function of a spe-
cific Stat for a noncytokine stimulus has yet to be estab-
lished; this is clearly the major challenge in this area. It
should be noted, though, that Stats are evolutionarily very
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this organism has not been reported to have Jaks [204,
205]. If this is the case, it would add credence to the
notion that Stats have broader functions beyond type I and
II cytokine signaling mediated by Jaks. Interestingly, v-src
and other oncogenes have been reported to activate Stats
and, importantly, a dominant-negative Stat3 construct has
been shown to block transformation [206]. Conversely, a
gain-of-function Stat3 construct is transforming [207]. The
importance of Stats in malignant transformation will need
to be established using knockout animals, but this is
clearly an exciting area.
Attenuation of cytokine signaling
Equally as important as the ability to initiate cytokine sig-
naling is the ability to terminate it. Indeed, one might spec-
ulate that this will be more important in terms of the
pathogenesis of human autoimmune diseases. The ability
to regulate cytokine signaling occurs by multiple proposed
mechanisms. These include the following: phosphatases,
cytokine-inducible inhibitor molecules, transcriptional
repressors, and Stat degradation (Fig. 4).
Phosphatases
It is well recognized that cytokine-induced phosphorylation of
various substrates, including the Jaks, cytokine receptors,
and the Stats, is transient. The tyrosine phosphatase SHP-1
has been hypothesized as one regulator that can interact
with cytokine receptors and downregulate their function
[208–210]. Interestingly, motheaten and viable motheaten
mice have a mutation in the gene that encodes SHP-1 and
exhibit many characteristics of systemic autoimmunity
[211–213]. Motheaten mice are characterized by increased
levels of plasma cells in secondary lymphoid organs with
abnormal levels of immunoglobulins and elevated serum anti-
double-stranded DNA antibodies, a peripheral neutrophilia
and monocytosis, decreased erythropoiesis, neutrophilic skin
lesions, and a severe pneumonitis that is induced by acti-
vated macrophages. These mice rarely live beyond 8 weeks
[214]. This striking presentation of autoimmune phenomena
suggests that some manifestations of human disease might
also be a result of aberrant downregulation of cytokine sig-
naling. The regulation of cytokine signaling via SHP-1 is also
important in bone remodeling, because motheaten mice
have recently been shown to develop osteopenia due to a
lack of SHP-1 mediated control of bone resorption [215].
Whether SHP-1 or another nuclear tyrosine phosphatase
is responsible for Stat dephosphorylation is not clear.
Indeed, one might speculate that a nuclear phosphatase
would be required. Because some Stats are also serine
phosphorylated, it is also reasonable to expect that a
serine phosphatase might also regulate Stat function.
Alternatively, it has been suggested that degradation of
Stats via ubiquitination is also a means of terminating Stat
induced signaling [216].
Suppressor of cytokine signaling/Jak binding/Stat-induced
Stat inhibitor/cytokine inducible SH2 protein family of
inhibitors
A recently described family of SH2-containing molecules
[alternatively named Jak binding, SOCS, Stat-induced
Stat inhibitor and cytokine inducible SH2 protein (CIS)]
comprises several molecules that are induced rapidly
upon cytokine stimulation and serve as classic feedback
inhibitors of signaling [11,217–220]. There are at least
eight members of this family characterized by a central
SH2 domain and a carboxy-terminal region of homology,
termed the ‘SOCS box’ (Fig. 1); for the purpose of this
paper, this family will be referred to as the ‘SOCS’ family.
The exact function of this region remains unclear at
present, but a recent study [221] has shown that the
SOCS box mediates interactions with elongins B and C.
In this manner, they may couple SOCS proteins and their
activated substrates to the proteasomal protein degrada-
tion pathway. The proteins SOCS-1, SOCS-3, and CIS-1
have been the most carefully studied in terms of regulating
cytokine signaling, and this is discussed further.
The first member of this family, CIS, was discovered in
1995 and was shown to associate with the IL-3 and ery-
thropoietin receptors [217]. Subsequently, three different
groups identified the second family member (named
SOCS-1, Jak binding, or Stat-induced Stat inhibitor-1)
based on its ability to interact with Jaks and/or inhibit Jak
mediated Stat activation [218,219]. Via their SH2
domains, some SOCS members bind the phosphorylated
activation loop tyrosine residue in Jaks, thereby inhibiting
Jak activity [219,222].
The importance of this downregulation is highlighted in
SOCS-1 knockout mice, which have marked growth retarda-
tion, display increased lymphocyte apoptosis, and perish
within 3 weeks of birth [223,224]. Two very recent studies of
these animals have shown that this lethality is due almost
entirely to systemic hyper-responsiveness to IFN-g and that
aberrant T lymphocytes may be the source of the IFN-g
[225,226]. Although these mice have enhanced IFN-g depen-
dent ability to kill Leishmania major parasites, they exhibit
exaggerated and lethal responses to viral infections. Defi-
ciency of SOCS-1 also results in impaired lymphopoiesis, as
thymi from these animals undergo a loss of cellularity and a
switch from predominantly CD4+CD8+ to single positive
cells. Additionally, peripheral T cells express activation
markers and respond to IL-2 in the absence of T-cell receptor
cross-linking. The relative specificity of SOCS-1 for IFN-g sig-
naling in this model is underscored by experiments that
demonstrate that all pathology can be prevented by adminis-
tering anti-IFN-g antibodies or by crossing the mice with IFN-g
knockout mice. Clearly, the main role of SOCS-1, therefore, is
to prevent uncontrolled and lethal IFN-g signaling. It is interest-
ing to speculate that SOCS-1 mutations or polymorphisms
could potentially underlie immunologic diseases in humans.
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vitro to interact with the Jaks to regulate Stat activation
[222,227,228]. However, a recent study in SOCS-3 defi-
cient mice reveals the critical role for this protein in down-
regulating fetal, but not adult, hematopoiesis [229]. This
suggests a more specific role for SOCS-3 in Jak2 regula-
tion, because Jak2 knockout mice have hematopoietic dis-
orders as well [66]. CIS-1, another member of this family,
may downregulate cytokine signaling by binding directly to
receptors, rather than Jaks. In this regard, CIS-1 has been
shown to interact with the IL-2 receptor b chain and inhibit
IL-2 dependent signaling [230]. Recently, CIS-1 transgenic
mice have been created, and their phenotype is remarkably
similar to those of Stat5a and Stat5b knockout mice, indi-
cating the critical role of CIS-1 as a negative regulator of
Stat5 function [231]. It is becoming more evident with time
that in vivo models are necessary to dissect the specificity
of SOCS interactions. Also, we are learning that SOCS
members may play a role in noncytokine signaling, includ-
ing the leptin, growth hormone, and prolactin signaling
pathways [232–234], but findings in SOCS knockout mice
do not necessarily support a critical function.
Protein inhibitors of activated Stats
Recently, a family of proteins that interact with Stats,
termed protein inhibitors of activated Stats (PIAS), have
been identified [235,236]. PIAS1 and PIAS3 bind to
Stat1 and Stat3, respectively. They inhibit transcriptional
activity of the Stats, but do not affect phosphorylation. Just
how specific they are in terms of regulating cytokine sig-
naling has not been determined; no knockouts have yet
been reported. In addition, these molecules were cloned
by yeast two-hybrid screens using baits other than Stat
molecules, and therefore may affect proteins other than
Stats. Thus, it will be important to characterize the physio-
logic function of this family of molecules.
Bcl-6
Bcl-6, a zinc-finger protein expressed in B cells and CD4+
T cells and frequently associated with non-Hodgkin’s lym-
phoma, has also been recently shown to regulate Stat
function negatively. Bcl-6 deficient mice develop a severe
systemic inflammatory disease typical of a Th2-mediated
hyperimmune response, which is characterized by infil-
trates of immunoglobulin E-bearing B cells and eosinophils
[237]. Because the Bcl-6 DNA recognition motif resem-
bles sites bound by Stat6, it was surprising to find that
when Bcl-6 mice were bred to either Stat6 or IL-4 deficient
mice, the animals still manifested the same hyperinflamma-
tory process. In vitro, however, Stat6 was required for the
differentiation of Bcl-6 deficient T cells into Th2 cells.
These findings indicate that this transcriptional repressor
can regulate Th2 responses by pathways both dependent
on and independent of IL-4 and Stat6 [238].
Conclusion
The Jaks are a small family of tyrosine kinases with very
specific functions; these are best illustrated by humans
with mutations and gene-targeted mice. The present
data indicate that they have critical functions in transmit-
ting cytokine-dependent signals. The Stats, too, appear
to be a small, but conserved family of transcription
factors that serve to further transmit signals initiated by
receptor–Jak interactions, also with highly specific func-
tions. Indeed, at least four of the six Stats have major
functions in regulating host defense and immune
responses. Although we have learned a great deal about
the cytokine signaling pathways, relatively few cytokine-
inducible genes have been identified. This, of course, will
rapidly change with the advent of microarray and gene
chip technologies. The challenge will remain to dissect
how Stats interact with the growing list of other tran-
scription factors to regulate the expression of these
genes and how signals emanating from cytokine recep-
tors affect transcriptional activation. Another important
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Figure 4
Attenuation of cytokine signaling. Suppressor of cytokine signaling
(SOCS) proteins are induced in response to cytokines and suppress
signal transduction in two ways. Some SOCS proteins bind directly to
janus kinases (Jaks) and inhibit their catalytic activity, whereas others
like cytokine inducible src homology-2 protein (CIS) can bind to
activated receptors and prevent docking by signaling intermediates
such as the Stats. SHP-1 can either dephosphorylate Jaks or activated
receptor subunits, depending upon the pathway activated. Protein
inhibitors of activated Stats (PIAS) family members inactivate Stat
dimers by an as yet unknown mechanism. Stat dimers are also
probably downregulated by degradation and dephosphorylated by
unknown mechanisms. The accumulation of STATs in the nucleus
could be regulated at the level of nuclear import, nuclear export, or a
combination of the two; the mechanisms that control these processes
are not well characterized. Finally, molecules like Bcl-6 can bind to
consensus Stat binding sites and function as repressors.
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P Pissue that needs to be resolved is to what extent Jaks
and Stats function as essential intermediates for noncy-
tokine receptors. Equally exciting as the discovery of the
Jaks and Stats is the discovery of families of molecules
that serve to attenuate cytokine signalling; it is exciting to
consider that these molecules might be mutated or poly-
morphic in human autoimmune diseases.
A knowledge of these signaling pathways is of particular
importance to rheumatologists, because cytokines clearly
regulate the inflammatory and immune responses. One
significant lesson gleaned from these investigations is that
cytokines may act as a double-edged sword: That is,
although cytokines play important physiologic roles in pro-
moting immune development and fighting off infections,
maladapted cytokine responses can lead to autoimmunity.
Perhaps a clearer understanding of how members of the
Jak and Stat families, as well as the more recently discov-
ered SOCS family members, interact and function may
allow us to target specific pathways, such as those involv-
ing proinflammatory cytokines including IFN-g or IL-6, for
therapeutic intervention. Knowledge in cytokine signaling
pathways has grown exponentially over the past decade
and, conceivably, manipulation of these pathways through
pharmaceutical intervention may provide the rheumatolo-
gist with a unique way to treat autoimmune diseases.
References
1. Darnell JEJ, Kerr IM, Stark GR: Jak-STAT pathways and transcrip-
tional activation in response to IFNs and other extracellular sig-
naling proteins. Science 1994, 264:1415–1421.
2. Pellegrini S, Dusanter-Fourt I: The structure, regulation and function
of the Janus kinases (JAKs) and the signal transducers and activa-
tors of transcription (STATs). Eur J Biochem 1997, 248:615–633.
3. Ihle JN, Thierfelder W, Teglund S, et al: Signaling by the cytokine
receptor superfamily. Ann N Y Acad Sci 1998, 865:1–9.
4. O’Shea JJ: Jaks, STATs, cytokine signal transduction, and
immunoregulation: are we there yet? Immunity 1997, 7:1–11.
5. Bach EA, Aguet M, Schreiber RD: The IFN-gamma receptor: a para-
digm for cytokine receptor signaling. Annu Rev Immunol 1997, 15:
563–593.
6. Leonard WJ, O’Shea JJ: Jaks and STATs: biological implications.
Annu Rev Immunol 1998, 16:293–322.
7. Carter-Su C, Smit LS: Signaling via JAK tyrosine kinases: growth
hormone receptor as a model system. Recent Prog Horm Res
1998,  53:61–82; discussion 82–83.
8. Aringer M, Cheng A, Nelson JW, et al: Janus kinases and their role
in growth and disease. Life Sci 1999, 64:2173–2186.
9. Hoey T, Grusby MJ: STATs as mediators of cytokine-induced
responses. Adv Immunol 1999, 71:145–162.
10. Starr R, Hilton DJ: Negative regulation of the JAK/STAT pathway.
Bioessays 1999, 21:47–52.
11. Hilton DJ: Negative regulators of cytokine signal transduction. Cell
Mol Life Sci 1999, 55:1568–1577.
12. Baird AM, Gerstein RM, Berg LJ: The role of cytokine receptor sig-
naling in lymphocyte development. Curr Opin Immunol 1999, 11:
157–166.
13. Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R: Identification
and chromosomal mapping of new human tyrosine kinase genes.
Oncogene 1990, 5:277–282.
14. Wilks AF, Harpur AG, Kurban RR, et al: Two novel protein-tyrosine
kinases, each with a second phosphotransferase-related catalytic
domain, define a new class of protein kinase. Mol Cell Biol 1991,
11:2057–2065.
15. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF: JAK2, a
third member of the JAK family of protein tyrosine kinases. Onco-
gene 1992, 7:1347–1353.
16. Kawamura M, McVicar DW, Johnston JA, et al: Molecular cloning of
L-JAK, a Janus family protein-tyrosine kinase expressed in natural
killer cells and activated leukocytes. Proc Natl Acad Sci USA 1994,
91:6374–6378.
17. Sofer L, Kampa D, Burnside J: Molecular cloning of a chicken JAK
homolog from activated T cells. Gene 1998, 215:29–36.
18. Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N: Activation
of a Drosophila Janus kinase (JAK) causes hematopoietic neopla-
sia and developmental defects. EMBO J 1995, 14:2857–2865.
19. Binari R, Perrimon N: Stripe-specific regulation of pair-rule genes
by hopscotch, a putative Jak family tyrosine kinase in Drosophila.
Genes Dev 1994, 8:300–312.
20. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O: Sig-
naling through the hematopoietic cytokine receptors. Annu Rev
Immunol 1995,  13:369–398.
21. Velazquez L, Fellous M, Stark GR, Pellegrini S: A protein tyrosine
kinase in the interferon alpha/beta signaling pathway. Cell 1992,
70:313–322.
22. Watling D, Guschin D, Muller M, et al: Complementation by the
protein tyrosine kinase JAK2 of a mutant cell line defective in the
interferon-gamma signal transduction pathway. Nature 1993, 366:
166–170.
23. Silvennoinen O, Ihle JN, Schlessinger J, Levy DE: Interferon-induced
nuclear signalling by Jak protein tyrosine kinases. Nature 1993,
366:583–585.
24. Witthuhn BA, Quelle FW, Silvennoinen O, et al: JAK2 associates
with the erythropoietin receptor and is tyrosine phosphorylated
and activated following stimulation with erythropoietin. Cell 1993,
74:227–236.
25. Argetsinger LS, Campbell GS, Yang X, et al: Identification of JAK2
as a growth hormone receptor-associated tyrosine kinase. Cell
1993,  74:237–244.
26. Witthuhn BA, Silvennoinen O, Miura O, et al: Involvement of the Jak-
3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid
and myeloid cells. Nature 1994, 370:153–157.
27. Johnston JA, Kawamura M, Kirken RA, et al: Phosphorylation and
activation of the Jak-3 Janus kinase in response to interleukin-2.
Nature 1994, 370:151–153.
28. Ihle JN: The Janus protein tyrosine kinase family and its role in
cytokine signaling. Adv Immunol 1995, 60:1–35.
29. Gurniak CB, Berg LJ: Murine JAK3 is preferentially expressed in
hematopoietic tissues and lymphocyte precursor cells. Blood
1996,  87:3151–3160.
30. Sharfe N, Dadi HK, Shahar M, Roifman CM: Human immune disor-
der arising from mutation of the alpha chain of the interleukin-2
receptor. Proc Natl Acad Sci USA 1997, 94:3168–3171.
31. Tortolani PJ, Lal BK, Riva A, et al: Regulation of JAK3 expression
and activation in human B cells and B cell malignancies. J
Immunol 1995, 155:5220–5226.
32. Musso T, Johnston JA, Linnekin D, et al: Regulation of JAK3 expres-
sion in human monocytes: phosphorylation in response to inter-
leukins 2, 4, and 7. J Exp Med 1995, 181:1425–1431.
33. Russell SM, Johnston JA, Noguchi M, et al: Interaction of IL-2R beta
and gamma c chains with Jak1 and Jak3: implications for XSCID
and XCID. Science 1994, 266:1042–1045.
34. Miyazaki T, Kawahara A, Fujii H, et al: Functional activation of Jak1
and Jak3 by selective association with IL-2 receptor subunits.
Science 1994,  266:1045–1047.
35. Boussiotis VA, Barber DL, Nakarai T, et al: Prevention of T cell
anergy by signaling through the gamma c chain of the IL-2 recep-
tor. Science 1994, 266:1039–1042.
36. Oakes SA, Candotti F, Johnston JA, et al: Signaling via IL-2 and IL-4
in JAK3-deficient severe combined immunodeficiency lympho-
cytes: JAK3-dependent and independent pathways. Immunity
1996,  5:605–615.
37. Candotti F, Oakes SA, Johnston JA, et al: In vitro correction of JAK3-
deficient severe combined immunodeficiency by retroviral-medi-
ated gene transduction. J Exp Med 1996, 183:2687–2692.
38. Macchi P, Villa A, Gillani S, et al: Mutations of Jak-3 gene in patients
with autosomal severe combined immune deficiency (SCID).
Nature 1995,  377:65–68.
39. Russell SM, Tayebi N, Nakajima H, et al: Mutation of Jak3 in a patient
with SCID: essential role of Jak3 in lymphoid development.
Science 1995,  270:797–800.
40. Noguchi M, Yi H, Rosenblatt HM, et al: Interleukin-2 receptor
gamma chain mutation results in X-linked severe combined
immunodeficiency in humans. Cell 1993, 73:147–157.
http://arthritis-research.com/content/2/1/016Arthritis Research    Vol 2 No 1 Ortmann et al
41. Nosaka T, van Deursen JM, Tripp RA, et al: Defective lymphoid
development in mice lacking Jak3. Science 1995, 270:800–802.
42. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ: Defects in B
lymphocyte maturation and T lymphocyte activation in mice
lacking Jak3. Science 1995, 270:794–797.
43. Park SY, Saijo K, Takahashi T, et al: Developmental defects of lym-
phoid cells in Jak3 kinase-deficient mice. Immunity 1995,
3:771–782.
44. Thomis DC, Berg LJ: The role of Jak3 in lymphoid development,
activation, and signaling. Curr Opin Immunol 1997, 9:541–547.
45. Maeurer MJ, Lotze MT: Interleukin-7 (IL-7) knockout mice. Implica-
tions for lymphopoiesis and organ-specific immunity. Int Rev
Immunol 1998,  16:309–322.
46. Maraskovsky E, Teepe M, Morrissey PJ, et al: Impaired survival and
proliferation in IL-7 receptor-deficient peripheral T cells. J Immunol
1996, 157:5315–5323.
47. von Freeden-Jeffry U, Vieira P, Lucian LA, et al: Lymphopenia in inter-
leukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant
cytokine. J Exp Med 1995, 181:1519–1526.
48. Puel A, Ziegler SF, Buckley RH, Leonard WJ: Defective IL7R expres-
sion in T(-)B(+)NK(+) severe combined immunodeficiency. Nature
Genet 1998, 20:394–397.
49. Lodolce JP, Boone DL, Chai S, et al: IL-15 receptor maintains lym-
phoid homeostasis by supporting lymphocyte homing and prolif-
eration. Immunity 1998, 9:669–676.
50. Candotti F, Oakes SA, Johnston JA, et al: Structural and functional
basis for JAK3-deficient severe combined immunodeficiency.
Blood 1997,  90:3996–4003.
51. Suzuki H, Kundig TM, Furlonger C, et al: Deregulated T cell activa-
tion and autoimmunity in mice lacking interleukin-2 receptor beta.
Science 1995, 268:1472–1476.
52. Willerford DM, Chen J, Ferry JA, et al: Interleukin-2 receptor alpha
chain regulates the size and content of the peripheral lymphoid
compartment. Immunity 1995, 3:521–530.
53. Fujii H, Ogasawara K, Otsuka H, et al: Functional dissection of
the cytoplasmic subregions of the IL-2 receptor betac chain in
primary lymphocyte populations. EMBO J 1998, 17:6551–
6557.
54. Saijo K, Park SY, Ishida Y, Arase H, Saito T: Crucial role of Jak3 in
negative selection of self-reactive T cells. J Exp Med 1997, 185:
351–356.
55. Brugnoni D, Notarangelo LD, Sottini A, et al: Development of autolo-
gous, oligoclonal, poorly functioning T lymphocytes in a patient
with autosomal recessive severe combined immunodeficiency
caused by defects of the Jak3 tyrosine kinase. Blood 1998, 91:
949–955.
56. Villa A, Sironi M, Macchi P, et al: Monocyte function in a severe
combined immunodeficient patient with a donor splice site muta-
tion in the Jak3 gene. Blood 1996, 88:817–823.
57. Colamonici O, Yan H, Domanski P, et al: Direct binding to and tyro-
sine phosphorylation of the alpha subunit of the type I interferon
receptor by p135tyk2 tyrosine kinase. Mol Cell Biol 1994, 14:
8133–8142.
58. Novick D, Cohen B, Rubinstein M: The human interferon alpha/beta
receptor: characterization and molecular cloning. Cell 1994, 77:
391–400.
59. Abramovich C, Shulman LM, Ratovitski E, et al: Differential tyrosine
phosphorylation of the IFNAR chain of the type I interferon recep-
tor and of an associated surface protein in response to IFN-alpha
and IFN-beta. EMBO J 1994, 13:5871–5877.
60. Muller M, Briscoe J, Laxton C, et al: The protein tyrosine kinase
JAK1 complements defects in interferon-alpha/beta and -gamma
signal transduction. Nature 1993, 366:129–135.
61. Quelle FW, Sato N, Witthuhn BA, et al: JAK2 associates with the
beta c chain of the receptor for granulocyte-macrophage colony-
stimulating factor, and its activation requires the membrane-proxi-
mal region. Mol Cell Biol 1994, 14:4335–4341.
62. Stahl N, Boulton TG, Farruggella T, et al: Association and activation
of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor compo-
nents. Science 1994, 263:92–95.
63. Zou J, Presky DH, Wu CY, Gubler U: Differential associations
between the cytoplasmic regions of the interleukin-12 receptor
subunits beta1 and beta2 and JAK kinases. J Biol Chem 1997,
272:6073–6077.
64. Rodig SJ, Meraz MA, White JM, et al: Disruption of the Jak1 gene
demonstrates obligatory and nonredundant roles of the Jaks in
cytokine-induced biologic responses. Cell 1998, 93:373–383.
65. Neubauer H, Cumano A, Muller M, et al: Jak2 deficiency defines an
essential developmental checkpoint in definitive hematopoiesis.
Cell 1998, 93:397–409.
66. Parganas E, Wang D, Stravopodis D, et al: Jak2 is essential for sig-
naling through a variety of cytokine receptors. Cell 1998,
93:385–395.
67. Lacronique V, Boureux A, Valle VD, et al: A TEL-JAK2 fusion protein
with constitutive kinase activity in human leukemia. Science 1997,
278:1309–1312.
68. Peeters P, Raynaud SD, Cools J, et al: Fusion of TEL, the ETS-
variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as
a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid
leukemia. Blood 1997,  90:2535–2540.
69. Hanissian SH, Geha RS: Jak3 is associated with CD40 and is criti-
cal for CD40 induction of gene expression in B cells. Immunity
1997,  6:379–387.
70. Jabara HH, Buckley RH, Roberts JL, et al: Role of JAK3 in CD40-
mediated signaling. Blood 1998, 92:2435–2440.
71. Rane SG, Reddy EP: JAK3: a novel JAK kinase associated with ter-
minal differentiation of hematopoietic cells. Oncogene 1994, 9:
2415–2423.
72. Lai KS, Jin Y, Graham DK, et al: A kinase-deficient splice variant of
the human JAK3 is expressed in hematopoietic and epithelial
cancer cells. J Biol Chem 1995, 270:25028–25036.
73. Hubbard SR, Wei L, Ellis L, Hendrickson WA: Crystal structure of
the tyrosine kinase domain of the human insulin receptor. Nature
1994, 372:746–754.
74. Gauzzi MC, Velazquez L, McKendry R, et al: Interferon-alpha-depen-
dent activation of Tyk2 requires phosphorylation of positive regu-
latory tyrosines by another kinase. J Biol Chem 1996, 271:
20494–20500.
75. Feng J, Witthuhn BA, Matsuda T, et al: Activation of Jak2 catalytic
activity requires phosphorylation of Y1007 in the kinase activation
loop. Mol Cell Biol 1997, 17:2497–2501.
76. Zhou YJ, Hanson EP, Chen YQ, et al: Distinct tyrosine phosphoryla-
tion sites in JAK3 kinase domain positively and negatively regu-
late its enzymatic activity. Proc Natl Acad Sci USA 1997, 94:
13850–13855.
77. Rui L, Mathews LS, Hotta K, Gustafson TA, Carter-Su C: Identifica-
tion of SH2-Bbeta as a substrate of the tyrosine kinase JAK2
involved in growth hormone signaling. Mol Cell Biol 1997, 17:
6633–6644.
78. Rui L, Carter-Su C: Identification of SH2-bbeta as a potent cyto-
plasmic activator of the tyrosine kinase Janus kinase 2. Proc Natl
Acad Sci USA 1999, 96:7172–7177.
79. Frank SJ, Gilliland G, Kraft AS, Arnold CS: Interaction of the growth
hormone receptor cytoplasmic domain with the JAK2 tyrosine
kinase. Endocrinology 1994,  135:2228–2239.
80. Luo H, Rose P, Barber D, et al: Mutation in the Jak kinase JH2
domain hyperactivates Drosophila and mammalian Jak-Stat path-
ways. Mol Cell Biol 1997, 17:1562–1571.
81. Fujitani Y, Hibi M, Fukada T, et al: An alternative pathway for STAT
activation that is mediated by the direct interaction between JAK
and STAT. Oncogene 1997, 14:751–761.
82. Frank SJ, Yi W, Zhao Y, et al: Regions of the JAK2 tyrosine kinase
required for coupling to the growth hormone receptor. J Biol
Chem 1995,  270:14776–14785.
83. Zhao Y, Wagner F, Frank SJ, Kraft AS: The amino-terminal portion
of the JAK2 protein kinase is necessary for binding and phospho-
rylation of the granulocyte-macrophage colony-stimulating factor
receptor beta c chain. J Biol Chem 1995, 270:13814–13818.
84. Kohlhuber F, Rogers NC, Watling D, et al: A JAK1/JAK2 chimera can
sustain alpha and gamma interferon responses. Mol Cell Biol
1997,  17:695–706.
85. Chen M, Cheng A, Chen YQ, et al: The amino terminus of JAK3 is
necessary and sufficient for binding to the common gamma chain
and confers the ability to transmit interleukin 2-mediated signals.
Proc Natl Acad Sci USA 1997, 94:6910–6915.
86. Cacalano NA, Migone TS, Bazan F, et al: Autosomal SCID caused
by a point mutation in the N-terminus of Jak3: mapping of the
Jak3-receptor interaction domain. EMBO J 1999, 18:1549–1558.
87. Yan H, Piazza F, Krishnan K, Pine R, Krolewski JJ: Definition of the
interferon-alpha receptor-binding domain on the TYK2 kinase. J
Biol Chem 1998, 273:4046–4051.
88. Richter MF, Dumenil G, Uze G, Fellous M, Pellegrini S: Specific contri-
bution of tyk2 JH regions to the binding and the expression of the
interferon alpha/beta receptor component IFNAR1. J Biol Chem
1998,  273:24723–24729.89. Takeshita T, Arita T, Higuchi M, et al: STAM, signal transducing
adaptor molecule, is associated with Janus kinases and involved
in signaling for cell growth and c-myc induction. Immunity 1997,
6:449–457.
90. Asao H, Sasaki Y, Arita T, et al: Hrs is associated with STAM, a signal-
transducing adaptor molecule. Its suppressive effect on cytokine-
induced cell growth. J Biol Chem 1997, 272:32785–32791.
91. Tanaka N, Kaneko K, Asao H, et al: Possible involvement of a novel
STAM-associated molecule “AMSH” in intracellular signal trans-
duction mediated by cytokines. J Biol Chem 1999, 274:
19129–19135.
92. Livnah O, Stura EA, Middleton SA, et al: Crystallographic evidence
for preformed dimers of erythropoietin receptor before ligand
activation. Science 1999,  283:987–990.
93. Remy I, Wilson IA, Michnick SW: Erythropoietin receptor activation by
a ligand-induced conformation change. Science 1999, 283:990–993.
94. Tibbles LA, Woodgett JR: The stress-activated protein kinase path-
ways. Cell Mol Life Sci 1999, 55:1230–1254.
95. Campbell KS: Signal transduction from the B cell antigen-receptor.
Curr Opin Immunol 1999, 11:256–264.
96. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE: The IL-4 recep-
tor: signaling mechanisms and biologic functions. Annu Rev
Immunol 1999,  17:701–738.
97. Kurosaki T: Genetic analysis of B cell antigen receptor signaling.
Annu Rev Immunol 1999, 17:555–592.
98. Hardy K, Chaudhri G: Activation and signal transduction via
mitogen-activated protein (MAP) kinases in T lymphocytes.
Immunol Cell Biol 1997, 75:528–545.
99. Su B, Karin M: Mitogen-activated protein kinase cascades and reg-
ulation of gene expression. Curr Opin Immunol 1996, 8:402–411.
100. Fu XY, Schindler C, Improta T, Aebersold R, Darnell JEJ: The proteins
of ISGF-3, the interferon alpha-induced transcriptional activator,
define a gene family involved in signal transduction. Proc Natl
Acad Sci USA 1992, 89:7840–7843.
101. Shuai K, Schindler C, Prezioso VR, Darnell JEJ: Activation of tran-
scription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA
binding protein. Science 1992, 258:1808–1812.
102. Zhong Z, Wen Z, Darnell JEJ: Stat3 and Stat4: members of the
family of signal transducers and activators of transcription. Proc
Natl Acad Sci USA 1004, 91:4806–4810.
103. Akira S, Nishio Y, Inoue M, et al: Molecular cloning of APRF, a novel IFN-
stimulated gene factor 3 p91-related transcription factor involved in
the gp130-mediated signaling pathway. Cell 1994, 77:63–71.
104. Yamamoto K, Quelle FW, Thierfelder WE, et al: Stat4, a novel
gamma interferon activation site-binding protein expressed in
early myeloid differentiation. Mol Cell Biol 1994, 14:4342–4349.
105. Quelle FW, Shimoda K, Thierfelder W, et al: Cloning of murine Stat6
and human Stat6, Stat proteins that are tyrosine phosphorylated
in responses to IL-4 and IL-3 but are not required for mitogenesis.
Mol Cell Biol 1995, 15:3336–3343.
106. Hou J, Schindler U, Henzel WJ, et al: An interleukin-4-induced tran-
scription factor: IL-4 Stat. Science 1994, 265:1701–1706.
107. Wakao H, Gouilleux F, Groner B: Mammary gland factor (MGF) is a
novel member of the cytokine regulated transcription factor gene
family and confers the prolactin response. EMBO J 1994, 13:2182–
2191. (Published erratum appears in EMBO J 1995, 14:854–855.)
108. Hou J, Schindler U, Henzel WJ, Wong SC, McKnight SL: Identifica-
tion and purification of human Stat proteins activated in response
to interleukin-2. Immunity 1995, 2:321–329.
109. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L: Cloning
and expression of Stat5 and an additional homologue (Stat5b)
involved in prolactin signal transduction in mouse mammary
tissue. Proc Natl Acad Sci USA 1995, 92:8831–8835.
110. Darnell JEJ: STATs and gene regulation. Science 1997, 277:
1630–1635.
111. Schindler C, Fu XY, Improta T, Aebersold R, Darnell JEJ: Proteins of
transcription factor ISGF-3: one gene encodes the 91-and 84-kDa
ISGF-3 proteins that are activated by interferon alpha. Proc Natl
Acad Sci USA 1992, 89:7836–7839.
112. Shuai K, Stark GR, Kerr IM, Darnell JEJ: A single phosphotyrosine
residue of Stat91 required for gene activation by interferon-
gamma. Science 1993,  261:1744–1746.
113. Greenlund AC, Morales MO, Viviano BL, et al: Stat recruitment by
tyrosine-phosphorylated cytokine receptors: an ordered
reversible affinity-driven process. Immunity 1995, 2:677–687.
114. Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL: Components
of a Stat recognition code: evidence for two layers of molecular
selectivity. Immunity 1995, 2:689–697.
115. Becker S, Groner B, Muller CW: Three-dimensional structure of the
Stat3beta homodimer bound to DNA. Nature 1998, 394:145–151.
116. Chen X, Vinkemeier U, Zhao Y, et al: Crystal structure of a tyrosine
phosphorylated STAT-1 dimer bound to DNA. Cell 1998, 93:
827–839.
117. Vinkemeier U, Moarefi I, Darnell JEJ, Kuriyan J: Structure of the
amino-terminal protein interaction domain of STAT-4. Science
1998,  279:1048–1052.
118. Xu X, Sun YL, Hoey T: Cooperative DNA binding and sequence-
selective recognition conferred by the STAT amino-terminal
domain. Science 1996,  273:794–797.
119. Mikita T, Campbell D, Wu P, Williamson K, Schindler U: Require-
ments for interleukin-4-induced gene expression and functional
characterization of Stat6. Mol Cell Biol 1996, 16:5811–5820.
120. John S, Vinkemeier U, Soldaini E, Darnell JEJ, Leonard WJ: The signif-
icance of tetramerization in promoter recruitment by Stat5. Mol
Cell Biol 1999, 19:1910–1918.
121. Bhattacharya S, Eckner R, Grossman S, et al: Cooperation of Stat2
and p300/CBP in signalling induced by interferon-alpha. Nature
1996, 383:344–347.
122. Zhang JJ, Vinkemeier U, Gu W, et al: Two contact regions between
Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl
Acad Sci USA 1996, 93:15092–15096.
123. Horvai AE, Xu L, Korzus E, et al: Nuclear integration of JAK/STAT
and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA
1997, 94:1074–1079.
124. Korzus E, Torchia J, Rose DW, et al: Transcription factor-specific
requirements for coactivators and their acetyltransferase func-
tions. Science 1998,  279:703–707.
125. Pfitzner E, Jahne R, Wissler M, Stoecklin E, Groner B: p300/CREB-
binding protein enhances the prolactin-mediated transcriptional
induction through direct interaction with the transactivation
domain of Stat5, but does not participate in the Stat5- mediated
suppression of the glucocorticoid response. Mol Endocrinol 1998,
12:1582–1593.
126. Zhu M, John S, Berg M, Leonard WJ: Functional association of Nmi
with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling.
Cell 1999, 96:121–130.
127. Stocklin E, Wissler M, Gouilleux F, Groner B: Functional interactions
between Stat5 and the glucocorticoid receptor. Nature 1996, 383:
726–728.
128. Moriggl R, Berchtold S, Friedrich K, et al: Comparison of the trans-
activation domains of Stat5 and Stat6 in lymphoid cells and
mammary epithelial cells. Mol Cell Biol 1997, 17:3663–3678.
129. Cella N, Groner B, Hynes NE: Characterization of Stat5a and Stat5b
homodimers and heterodimers and their association with the glu-
cocortiocoid receptor in mammary cells. Mol Cell Biol 1998, 18:
1783–1792.
130. Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ: Stat1
depends on transcriptional synergy with Sp1. J Biol Chem 1995,
270:30264–30267.
131. Schaefer TS, Sanders LK, Nathans D: Cooperative transcriptional
activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad
Sci USA 1995, 92:9097–9101.
132. Shen CH, Stavnezer J: Interaction of stat6 and NF-kappaB: direct
association and synergistic activation of interleukin-4-induced
transcription. Mol Cell Biol 1998, 18:3395–3404.
133. Wen Z, Zhong Z, Darnell JEJ: Maximal activation of transcription by
Stat1 and Stat3 requires both tyrosine and serine phosphoryla-
tion. Cell 1995, 82:241–250.
134. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S: Requirement of
serine phosphorylation for formation of STAT-promoter com-
plexes. Science 1995,  267:1990–1994.
135. Wen Z, Darnell JEJ: Mapping of Stat3 serine phosphorylation to a
single residue (727) and evidence that serine phosphorylation
has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids
Res 1997, 25:2062–2067.
136. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JEJ: Tran-
scriptionally active Stat1 is required for the antiproliferative
effects of both interferon alpha and interferon gamma. Proc Natl
Acad Sci USA 1996, 93:7673–7678.
137. Moriggl R, Gouilleux-Gruart V, Jahne R, et al: Deletion of the car-
boxyl-terminal transactivation domain of MGF-Stat5 results in
sustained DNA binding and a dominant negative phenotype. Mol
Cell Biol 1996, 16:5691–5700.
138. Cho SS, Bacon CM, Sudarshan C, et al: Activation of STAT4 by IL-12
and IFN-alpha: evidence for the involvement of ligand-induced tyro-
sine and serine phosphorylation. J Immunol 1996, 157:4781–4789.
http://arthritis-research.com/content/2/1/016Arthritis Research    Vol 2 No 1 Ortmann et al
139. Beadling C, Ng J, Babbage JW, Cantrell DA: Interleukin-2 activation
of STAT5 requires the convergent action of tyrosine kinases and a
serine/threonine kinase pathway distinct from the Raf1/ERK2
MAP kinase pathway. EMBO J 1996, 15:1902–1913.
140. Yamashita H, Xu J, Erwin RA, et al: Differential control of the phos-
phorylation state of proline-juxtaposed serine residues ser725 of
stat5a and ser730 of stat5b in prolactin-sensitive cells. J Biol
Chem 1998,  273:30218–30224.
141. Woetmann A, Nielsen M, Christensen ST, et al: Inhibition of protein
phosphatase 2A induces serine/threonine phosphorylation, sub-
cellular redistribution, and functional inhibition of STAT3. Proc Natl
Acad Sci USA 1999, 96:10620–10625.
142. Zauberman A, Zipori D, Krupsky M, Ben-Levy R: Stress activated
protein kinase p38 is involved in IL-6 induced transcriptional acti-
vation of STAT3. Oncogene 1999, 18:3886–3893.
143. Turkson J, Bowman T, Adnane J, et al: Requirement for Ras/Rac1-
mediated p38 and c-Jun N-terminal kinase signaling in stat3 tran-
scriptional activity induced by the src oncoprotein. Mol Cell Biol
1999, 19:7519–7528.
144. Bode JG, Gatsios P, Ludwig S, et al: The mitogen-activated protein
(MAP) kinase p38 and its upstream activator MAP kinase kinase 6
are involved in the activation of signal transducer and activator of
transcription by hyperosmolarity. J Biol Chem 1999, 274:30222–
30227.
145. Goh KC, Haque SJ, Williams BR: p38 MAP kinase is required for
STAT1 serine phosphorylation and transcriptional activation
induced by interferons. EMBO J 1999, 18:5601–5608.
146. Lim CP, Cao X: Serine phosphorylation and negative regulation of
stat3 by JNK. J Biol Chem 1999, 274:31055–31061.
147. David M, Petricoin ER, Benjamin C, et al: Requirement for MAP
kinase (ERK2) activity in interferon alpha- and interferon beta-
stimulated gene expression through STAT proteins. Science 1995,
269:1721–1723.
148. Chung J, Uchida E, Grammer TC, Blenis J: STAT3 serine phosphory-
lation by ERK-dependent and -independent pathways negatively
modulates its tyrosine phosphorylation. Mol Cell Biol 1997, 17:
6508–6516.
149. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB: Rapid inhibition of
interleukin-6 signaling and stat3 activation mediated by mitogen-
activated protein kinases. Proc Natl Acad Sci USA 1998, 95:
11107–11112.
150. Strehlow I, Schindler C: Amino-terminal signal transducer and acti-
vator of transcription (STAT) domains regulate nuclear transloca-
tion and STAT deactivation. J Biol Chem 1998, 273:28049–28056.
151. Sekimoto T, Nakajima K, Tachibana T, Hirano T, Yoneda Y: Interferon-
gamma-dependent nuclear import of Stat1 is mediated by the
GTPase activity of Ran/TC4. J Biol Chem 1996, 271:31017–31020.
152. Sekimoto T, Yoneda Y: Nuclear import and export of proteins: the
molecular basis for intracellular signaling. Cytokine Growth Factor
Rev 1998, 9:205–211.
153. Ullman KS, Powers MA, Forbes DJ: Nuclear export receptors: from
importin to exportin. Cell 1997, 90:967–970.
154. Gorlich D: Transport into and out of the cell nucleus. EMBO J
1998,  17:2721–2727.
155. Subramaniam PS, Mujtaba MG, Paddy MR, Johnson HM: The carboxyl
terminus of interferon-gamma contains a functional polybasic
nuclear localization sequence. J Biol Chem 1999, 274:403–407.
156. Johnson HM, Torres BA, Green MM, et al: Hypothesis: ligand/recep-
tor-assisted nuclear translocation of STATs. Proc Soc Exp Biol
Med 1998,  218:149–155.
157. Car BD, Eng VM, Schnyder B, et al: Interferon gamma receptor
deficient mice are resistant to endotoxic shock. J Exp Med 1994,
179:1437–1444.
158. Durbin JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption
of the mouse Stat1 gene results in compromised innate immunity
to viral disease. Cell 1996, 84:443–450.
159. Meraz MA, White JM, Sheehan KC, et al: Targeted disruption of the
Stat1 gene in mice reveals unexpected physiologic specificity in
the JAK-STAT signaling pathway. Cell 1996, 84:431–442.
160. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al: A human
IFNGR1 small deletion hotspot associated with dominant suscep-
tibility to mycobacterial infection. Nature Genet 1999, 21:370–378.
161. Sahni M, Ambrosetti DC, Mansukhani A, et al: FGF signaling inhibits
chondrocyte proliferation and regulates bone development
through the STAT-1 pathway. Genes Dev 1999, 13:1361–1366.
162. Kaplan DH, Shankaran V, Dighe AS, et al: Demonstration of an inter-
feron gamma-dependent tumor surveillance system in immuno-
competent mice. Proc Natl Acad Sci USA 1998, 95:7556–7561.
163. Fallarino F, Gajewski TF: Cutting edge: differentiation of antitumor
CTL In vivo requires host expression of stat1. J Immunol 1999,
163:4109–4113.
164. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR: Defec-
tive TNF-alpha-induced apoptosis in STAT1-null cells due to low
constitutive levels of caspases. Science 1997, 278:1630–1632.
165. Tanaka N, Sato M, Lamphier MS, et al: Type I interferons are essen-
tial mediators of apoptotic death in virally infected cells. Genes
Cells 1998, 3:29–37.
166. Bluyssen HA, Levy DE: Stat2 is a transcriptional activator that
requires sequence-specific contacts provided by stat1 and p48 for
stable interaction with DNA. J Biol Chem 1997, 272:4600–4605.
167. Takeda K, Noguchi K, Shi W, et al: Targeted disruption of the
mouse Stat3 gene leads to early ‘embryonic’ lethality. Proc Natl
Acad Sci USA 1997, 94:3801–3804.
168. Escary JL, Perreau J, Dumenil D, Ezine S, Brulet P: Leukaemia
inhibitory factor is necessary for maintenance of haematopoietic
stem cells and thymocyte stimulation. Nature 1993, 363:361–364.
169. Takeda K, Clausen BE, Kaisho T, et al: Enhanced Th1 activity and
development of chronic enterocolitis in mice devoid of Stat3 in
macrophages and neutrophils. Immunity 1999, 10:39–49.
170. Wang KS, Ritz J, Frank DA: IL-2 induces STAT4 activation in
primary NK cells and NK cell lines, but not in T cells. J Immunol
1999, 162:299–304.
171. Kaplan MH, Sun YL, Hoey T, Grusby MJ: Impaired IL-12 responses
and enhanced development of Th2 cells in Stat4-deficient mice.
Nature 1996, 382:174–177.
172. Magram J, Connaughton SE, Warrier RR, et al: IL-12-deficient mice
are defective in IFN gamma production and type 1 cytokine
responses. Immunity 1996,  4:471–481.
173. Wu C, Ferrante J, Gately MK, Magram J: Characterization of IL-12
receptor beta1 chain (IL-12Rbeta1)-deficient mice: IL-12Rbeta1 is
an essential component of the functional mouse IL-12 receptor. J
Immunol 1997, 159:1658–1665.
174. de Jong R, Altare F, Haagen IA, et al: Severe mycobacterial and Sal-
monella infections in interleukin-12 receptor-deficient patients.
Science 1998,  280:1435–1438.
175. Lin JX, Mietz J, Modi WS, John S, Leonard WJ: Cloning of human
Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B
DNA binding activity in COS-7 cells. J Biol Chem 1996, 271:
10738–10744.
176. Liu X, Robinson GW, Wagner KU, et al: Stat5a is mandatory for
adult mammary gland development and lactogenesis. Genes Dev
1997, 11:179–186.
177. Udy GB, Towers RP, Snell RG, et al: Requirement of STAT5b for
sexual dimorphism of body growth rates and liver gene expres-
sion. Proc Natl Acad Sci USA 1997, 94:7239–7244.
178. Teglund S, McKay C, Schuetz E, et al: STAT5a and STAT5b proteins
have essential and nonessential, or redundant, roles in cytokine
responses. Cell 1998, 93:841–850.
179. Moriggl R, Topham DJ, Teglund S, et al: Stat5 is required for IL-2-
induced cell cycle progression of peripheral T cells. Immunity
1999,  10:249–259.
180. Nakajima H, Liu XW, Wynshaw-Boris A, et al: An indirect effect of
Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-
2-mediated IL-2 receptor alpha chain induction. Immunity 1997, 7:
691–701.
181. Imada K, Bloom ET, Nakajima H, et al: Stat5b is essential for natural
killer cell-mediated proliferation and cytolytic activity. J Exp Med
1998, 188:2067–2074.
182. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF: Fetal
anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice:
a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98:181–191.
183. Beadling C, Guschin D, Witthuhn BA, et al: Activation of JAK
kinases and STAT proteins by interleukin-2 and interferon alpha,
but not the T cell antigen receptor, in human T lymphocytes.
EMBO J 1994, 13:5605–5615.
184. Welte T, Leitenberg D, Dittel BN, et al: STAT5 interaction with the T
cell receptor complex and stimulation of T cell proliferation.
Science 1999,  283:222–225.
185. Gerwien J, Nielsen M, Labuda T, et al: Cutting edge: TCR stimulation
by antibody and bacterial superantigen induces stat3 activation in
human T cells. J Immunol 1999, 163:1742–1745.
186. Kaplan MH, Schindler U, Smiley ST, Grusby MJ: Stat6 is required for
mediating responses to IL-4 and for development of Th2 cells.
Immunity 1996, 4:313–319.187. Takeda K, Tanaka T, Shi W, et al: Essential role of Stat6 in IL-4 sig-
nalling. Nature 1996, 380:627–630.
188. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S: Impaired IL-
13-mediated functions of macrophages in STAT6-deficient mice. J
Immunol 1996, 157:3220–3222.
189. Shimoda K, van Deursen J, Sangster MY, et al: Lack of IL-4-induced
Th2 response and IgE class switching in mice with disrupted
Stat6 gene. Nature 1996, 380:630–633.
190. Akimoto T, Numata F, Tamura M, et al: Abrogation of bronchial
eosinophilic inflammation and airway hyperreactivity in signal
transducers and activators of transcription (STAT)6-deficient
mice. J Exp Med 1998, 187:1537–1542.
191. Kuperman D, Schofield B, Wills-Karp M, Grusby MJ: Signal trans-
ducer and activator of transcription factor 6 (Stat6)- deficient mice
are protected from antigen-induced airway hyperresponsiveness
and mucus production. J Exp Med 1998, 187:939–948.
192. Miller RL, Eppinger TM, McConnell D, Cunningham-Rundles C, Rothman
P: Analysis of cytokine signaling in patients with extrinsic asthma and
hyperimmunoglobulin E. J Allergy Clin Immunol 1998, 102:503–511.
193. Miyata S, Matsuyama T, Kodama T, et al: STAT6 deficiency in a
mouse model of allergen-induced airways inflammation abolishes
eosinophilia but induces infiltration of CD8+ T cells. Clin Exp
Allergy 1999,  29:114–123.
194. Kaplan MH, Whitfield JR, Boros DL, Grusby MJ: Th2 cells are
required for the Schistosoma mansoni egg-induced granuloma-
tous response. J Immunol 1998, 160:1850–1856.
195. Morse HCR, McCarty T, Giese NA, Taddesse-Heath L, Grusby MJ:
STAT6-deficient mice exhibit normal induction of murine AIDS
and expression of immunoglobulin E following infection with LP-
BM5 murine leukemia viruses. J Virol 1999, 73:7093–7095.
196. Kaplan MH, Wurster AL, Grusby MJ: A signal transducer and activa-
tor of transcription (Stat)4-independent pathway for the develop-
ment of T helper type 1 cells. J Exp Med 1998, 188:1191–1196.
197. Cantrell D: T cell antigen receptor signal transduction pathways.
Annu Rev Immunol 1996, 14:259–274.
198. David M, Wong L, Flavell R, et al: STAT activation by epidermal
growth factor (EGF) and amphiregulin. Requirement for the EGF
receptor kinase but not for tyrosine phosphorylation sites or JAK1.
J Biol Chem 1996, 271:9185–9188.
199. Zhong Z, Wen Z, Darnell JEJ: Stat3: a STAT family member acti-
vated by tyrosine phosphorylation in response to epidermal
growth factor and interleukin-6. Science 1994, 264:95–98.
200. Leaman DW, Pisharody S, Flickinger TW, et al: Roles of JAKs in acti-
vation of STATs and stimulation of c-fos gene expression by epi-
dermal growth factor. Mol Cell Biol 1996, 16:369–375.
201. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM: Acti-
vation of the STAT pathway by angiotensin II in T3CHO/AT1A
cells. Cross-talk between angiotensin II and interleukin-6 nuclear
signaling. J Biol Chem 1995, 270:19059–19065.
202. Marrero MB, Schieffer B, Paxton WG, et al: Direct stimulation of
Jak/STAT pathway by the angiotensin II AT1 receptor. Nature
1995,  375:247–250.
203. Mellado M, Rodriguez-Frade JM, Aragay A, et al: The chemokine
monocyte chemotactic protein 1 triggers Janus kinase 2 activation
and tyrosine phosphorylation of the CCR2B receptor. J Immunol
1998, 161:805–813.
204. Kawata T, Shevchenko A, Fukuzawa M, et al: SH2 signaling in a
lower eukaryote: a STAT protein that regulates stalk cell differen-
tiation in dictyostelium. Cell 1997, 89:909–916.
205. Mohanty S, Jermyn KA, Early A, et al: Evidence that the Dic-
tyostelium Dd-STATa protein is a repressor that regulates com-
mitment to stalk cell differentiation and is also required for
efficient chemotaxis. Development 1999, 126:3391–3405.
206. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JEJ: Stat3
activation is required for cellular transformation by v-src. Mol Cell
Biol 1998, 18:2553–2558.
207. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an onco-
gene. Cell 1999, 98:295–303.
208. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF: Specific
recruitment of SH-PTP1 to the erythropoietin receptor causes
inactivation of JAK2 and termination of proliferative signals. Cell
1995, 80:729–738.
209. Haque SJ, Harbor P, Tabrizi M, Yi T, Williams BR: Protein-tyrosine
phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-depen-
dent signal transduction. J Biol Chem 1998, 273:33893–33896.
210. Migone TS, Cacalano NA, Taylor N, et al: Recruitment of SH2-con-
taining protein tyrosine phosphatase SHP-1 to the interleukin 2
receptor; loss of SHP-1 expression in human T-lymphotropic virus
type I-transformed T cells. Proc Natl Acad Sci USA 1998, 95:
3845–3850.
211. Tsui HW, Siminovitch KA, de Souza L, Tsui FW: Motheaten and
viable motheaten mice have mutations in the haematopoietic cell
phosphatase gene. Nature Genet 1993, 4:124–129.
212. Bignon JS, Siminovitch KA: Identification of PTP1C mutation as the
genetic defect in motheaten and viable motheaten mice: a step
toward defining the roles of protein tyrosine phosphatases in the
regulation of hemopoietic cell differentiation and function. Clin
Immunol Immunopathol 1994, 73:168–179.
213. Shultz LD, Schweitzer PA, Rajan TV, et al: Mutations at the murine
motheaten locus are within the hematopoietic cell protein-tyro-
sine phosphatase (Hcph) gene. Cell 1993, 73:1445–1454.
214. Green MC, Shultz LD: Motheaten, an immunodeficient mutant of
the mouse. I. Genetics and pathology. J Hered 1975, 66:250–258.
215. Aoki K, Didomenico E, Sims NA, et al: The tyrosine phosphatase
SHP-1 is a negative regulator of osteoclastogenesis and osteo-
clast resorbing activity: increased resorption and osteopenia in
me(v)/me(v) mutant mice. Bone 1999, 25:261–267.
216. Kim TK, Maniatis T: Regulation of interferon-gamma-activated
STAT1 by the ubiquitin-proteasome pathway. Science 1996, 273:
1717–1719.
217. Yoshimura A, Ohkubo T, Kiguchi T, et al: A novel cytokine-inducible
gene CIS encodes an SH2-containing protein that binds to tyro-
sine-phosphorylated interleukin 3 and erythropoietin receptors.
EMBO J 1995, 14:2816–2826.
218. Starr R, Willson TA, Viney EM, et al: A family of cytokine-inducible
inhibitors of signalling. Nature 1997, 387:917–921.
219. Endo TA, Masuhara M, Yokouchi M, et al: A new protein containing an
SH2 domain that inhibits JAK kinases. Nature 1997, 387:921–924.
220. Naka T, Narazaki M, Hirata M, et al: Structure and function of a new
STAT-induced STAT inhibitor. Nature 1997, 387:924–929.
221. Zhang JG, Farley A, Nicholson SE, et al: The conserved SOCS box
motif in suppressors of cytokine signaling binds to elongins B and
C and may couple bound proteins to proteasomal degradation.
Proc Natl Acad Sci USA 1999, 96:2071–2076.
222. Sasaki A, Yasukawa H, Suzuki A, et al: Cytokine-inducible SH2
protein-3 (CIS3/SOCS3) inhibits janus tyrosine kinase by binding
through the N-terminal kinase inhibitory region as well as SH2
domain. Genes Cells 1999, 4:339–351.
223. Naka T, Matsumoto T, Narazaki M, et al: Accelerated apoptosis of
lymphocytes by augmented induction of Bax in SSI-1 (STAT-
induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA
1998, 95:15577–15582.
224. Starr R, Metcalf D, Elefanty AG, et al: Liver degeneration and lym-
phoid deficiencies in mice lacking suppressor of cytokine signal-
ing-1. Proc Natl Acad Sci USA 1998, 95:14395–14399.
225. Alexander WS, Starr R, Fenner JE, et al: SOCS1 is a critical inhibitor
of interferon gamma signaling and prevents the potentially fatal
neonatal actions of this cytokine. Cell 1999, 98:597–608.
226. Marine JC, Topham DJ, McKay C, et al: SOCS1 deficiency causes a
lymphocyte-dependent perinatal lethality. Cell 1999, 98:609–616.
227. Adams TE, Hansen JA, Starr R, et al: Growth hormone preferentially
induces the rapid, transient expression of SOCS-3, a novel inhibitor
of cytokine receptor signaling. J Biol Chem 1998, 273:1285–1287.
228. Cohney SJ, Sanden D, Cacalano NA, et al: SOCS-3 is tyrosine phos-
phorylated in response to interleukin-2 and suppresses STAT5
phosphorylation and lymphocyte proliferation. Mol Cell Biol 1999,
19:4980–4988.
229. Marine JC, McKay C, Wang D, et al: SOCS3 is essential in the regu-
lation of fetal liver erythropoiesis. Cell 1999, 98:617–627.
230. Aman MJ, Migone TS, Sasaki A, et al: CIS associates with the inter-
leukin-2 receptor beta chain and inhibits interleukin-2-dependent
signaling. J Biol Chem 1999, 274:30266–30272.
231. Matsumoto A, Seki Y, Kubo M, et al: Suppression of STAT5 func-
tions in liver, mammary glands, and T cells in cytokine-inducible
SH2-containing protein 1 transgenic mice. Mol Cell Biol 1999, 19:
6396–6407.
232. Pezet A, Favre H, Kelly PA, Edery M: Inhibition and restoration of
prolactin signal transduction by suppressors of cytokine signaling.
J Biol Chem 1999, 274:24497–24502.
233. Karlsson H, Gustafsson JA, Mode A: Cis desensitizes GH induced
Stat5 signaling in rat liver cells. Mol Cell Endocrinol 1999, 154:37–43.
234. Bjorbaek C, Elmquist JK, El-Haschimi K, et al: Activation of SOCS-3
messenger ribonucleic acid in the hypothalamus by ciliary neu-
rotrophic factor. Endocrinology 1999, 140:2035–2043.
http://arthritis-research.com/content/2/1/016Arthritis Research    Vol 2 No 1 Ortmann et al
235. Liu B, Liao J, Rao X, et al: Inhibition of Stat1-mediated gene activa-
tion by PIAS1. Proc Natl Acad Sci USA 1998, 95:10626–10631.
236. Chung CD, Liao J, Liu B, et al: Specific inhibition of Stat3 signal
transduction by PIAS3. Science 1997, 278:1803–1805.
237. Ye BH, Cattoretti G, Shen Q, et al: The BCL-6 proto-oncogene con-
trols germinal-centre formation and Th2-type inflammation. Nature
Genet 1997, 16:161–170.
238. Dent AL, Hu-Li J, Paul WE, Staudt LM: T helper type 2 inflammatory
disease in the absence of interleukin 4 and transcription factor
STAT6. Proc Natl Acad Sci USA 1998, 95:13823–13828.
Authors’ affiliations: Robert A Ortmann, David M Frucht, Roberta
Visconti and John J O’Shea (Lymphocyte Cell Biology Section, Arthritis
and Rheumatism Branch, National Institute of Arthritis, Musculoskeletal
and Skin Diseases, National Institutes of Health, Bethesda, Maryland,
USA), and Tammy Cheng (Howard Hughes Medical Institute-NIH
Scholars Program, Bethesda, Maryland, USA)
Correspondence: Robert A Ortmann, MD, Lymphocyte Cell Biology
Section, Arthritis and Rheumatism Branch, National Institute of
Arthritis, Musculoskeletal and Skin Diseases, National Institutes of
Health, Building 10 Room 9N262, Bethesda, MD 20892, USA.
Tel: +1 301 496 2541; e-mail: ro10j@nih.gov